HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Positive 64.8%

Neg 0% Neu 0% Pos 64.8%

HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $8.